Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Introduction: Liver cancer is one of the most common tumors in the world. Patients with liver cancer usually face substantial physical, psychological, and social burdens, which has created a great demand and expectation to ease the burden in all aspects. This study aimed to develop and validate the Treatment Expectation Scale for patients with Liver Cancer (TES-LC).
Material And Methods: The study was conducted in three phases. In the first stage, we used literature reviews and semi-structured interviews to generate the items to be included in the questionnaire TES-LC (version 1). In the second stage, two rounds of the Delphi expert consultation method were used to modify the first version to form TES-LC (version 2). In the third stage, projects were selected through project analysis and exploratory factor analysis to create TES-LC (version 3); then version 3 was tested for reliability and validity to generate version 4.
Results: The final version of the TES-LC contains 19 items in 5 dimensions: disease symptoms, practical needs, psychological state, emotional satisfaction, and social function. Five common factors were extracted through exploratory factor analysis, explaining 60.11% of the variance. In the validation factor analysis, the fitting effect of the five-factor model was satisfactory after modification. The TES-LC had good internal consistency, with a Cronbach's α coefficient of 0.911 for the total scale.
Conclusions: The TES-LC developed in this study has good reliability and validity and can provide a standardized tool for measuring treatment expectancy in patients with liver cancer, which is of good clinical utility.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11831337 | PMC |
| http://dx.doi.org/10.5114/aoms/186875 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
EphA3/EFNA3 Reverse Signalling Promotes Epithelial-to-Mesenchymal Transition via ERK Pathway to Facilitate Colorectal Cancer Metastasis.
Dig Dis Sci
September 2025
Department of Gastroenterology and Hepatology, West China Hospital of Sichuan University, Chengdu, Sichuan, China.
Background And Aims: Liver metastasis significantly contributes to poor survival in patients with colorectal cancer (CRC), posing therapeutic challenges due to limited understanding of its mechanisms. We aimed to identify a potential target critical for CRC liver metastasis.
Methods: We analyzed the Gene Expression Omnibus (GEO) and the Cancer Genome Atlas (TCGA) databases and identified EphrinA3 (EFNA3) as a potential clinically relevant target.
Is there a chance for curative treatment for metastatic pancreatic adenocarcinoma? A systematic review with meta-analysis.
Langenbecks Arch Surg
September 2025
Department of Surgery HBP Unit, Simone Veil Hospital, University of Reims Champagne-Ardenne, Troyes, France.
Introduction: Pancreatic adenocarcinomas (PDAC) have a poor prognosis, with a 5-year relative Survival rate of 11.5%. Only 20% of patients are initially eligible for resection, and 50% of patients presented with metastatic disease, currently only candidates' palliative treatment.
View Article and Find Full Text PDFCT-Based Radiomics Models with External Validation for Prediction of Recurrence and Disease-Specific Mortality After Radical Surgery of Colorectal Liver Metastases.
Ann Surg Oncol
September 2025
HepatoBiliaryPancreatic Surgery, AOU Careggi, Department of Experimental and Clinical Medicine (DMSC), University of Florence, Florence, Italy.
Purpose: To build computed tomography (CT)-based radiomics models, with independent external validation, to predict recurrence and disease-specific mortality in patients with colorectal liver metastases (CRLM) who underwent liver resection.
Methods: 113 patients were included in this retrospective study: the internal training cohort comprised 66 patients, while the external validation cohort comprised 47. All patients underwent a CT study before surgery.
Expert consensus regarding the clinical application of liver contrast-enhanced US with Sonazoid (Sonazoid CEUS).
Int J Surg
September 2025
Department of Interventional Ultrasound, Fifth Medical Center of Chinese PLA General Hospital, Beijing, China.
Sonazoid, a combined blood pool and Kupffer-cell agent, can be specifically phagocytosed by Kupffer cells in the liver, allowing lesion detection and characterization of focal liver lesions (FLLs) at the post-vascular phase apart from the vascular phase which is similar to that of other second-generation US contrast agents. Sonazoid CEUS is currently approved for use in some Asian countries. With the increasing use of Sonazoid CEUS for FLLs in clinical practice, developing consensus or guidelines to help standardize its use is required.
View Article and Find Full Text PDFImpact of child-pugh score on surgical outcomes after distal gastrectomy and right hemicolectomy: a retrospective study from the Japanese national clinical database.
Int J Surg
September 2025
The Japanese Society of Gastroenterological Surgery, Tokyo, Japan.
Background: The association between preoperative liver function and short-term outcomes after gastrointestinal cancer surgery is unknown. This study investigated the impact of Child-Pugh score-based preoperative liver dysfunction on short-term outcomes after distal gastrectomy and right hemicolectomy.
Materials And Methods: We included patients who underwent distal gastrectomy for gastric cancer or right hemicolectomy for colon cancer between 2018 and 2022 from the Japanese National Clinical Database.